Startup Details

Mridu Sinha

CEO

MelioLabs, Inc.

Company Name

MelioLabs, Inc.

Company Website

http://www.melio.tech

Industry

Med-Tech

Location

UNITED STATES

Developmental Stage

*********

Approx Revenue for current Year

*********

Type of funding

*********

Pre-money Valuation (USD)

*********

Type of offering

*********

Amount of Capital seeking in current round (USD)

*********

Previous capital raised (USD)

Monthly Burn rate (USD)

Company Description

Melio is developing its product portfolio based on proprietary AI-enabled DNA melting technology for rapid and accurate identification of pathogen targets. The technology platform enables identification and quantification of up to 80 pathogen targets in a single culture-free test. Melio's current efforts are focused on delivering a low-cost, in-hou... Read more

Product/Service Description

Melio's first product will test for most common 30 bacteria, fungi and viruses responsible for 98% of neonatal sepsis cases from the small volume newborn blood samples providing 5X more coverage over the state of art FDA approved tests. Our platform will be competitively priced, and our business model focuses on selling single-use cartridges. As th... Read more

Management Team

Mridu Sinha

CEO

Mridu Sinha

CEO

Claude Benchimol

COO

Todd Peterson

Head of Product Development

Mamatha Shekar

Head of Clinical Assay & Development

Advisor Team

Previous Investors

MIT Angels

NIH

MIT Angels

Ronjon Nag

Company Information

Date Company Founded
06/30/2018
Registered Location
Delaware
Legal Name
MelioLabs, Inc.
Date Company Registered
06/30/2018
Address
, Santa Clara, CA, CA
Country
UNITED STATES